These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 28815476)

  • 1. Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT Registry.
    Menter A; Thaçi D; Wu JJ; Abramovits W; Kerdel F; Arikan D; Guo D; Ganguli A; Bereswill M; Camez A; Valdecantos WC
    Dermatol Ther (Heidelb); 2017 Sep; 7(3):365-381. PubMed ID: 28815476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis.
    Menter A; Thaçi D; Papp KA; Wu JJ; Bereswill M; Teixeira HD; Rubant S; Williams DA
    J Am Acad Dermatol; 2015 Sep; 73(3):410-9.e6. PubMed ID: 26190240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic review of the real-world evidence of adalimumab safety in psoriasis registries.
    Strober B; Crowley J; Langley RG; Gordon K; Menter A; Leonardi C; Arikan D; Valdecantos WC
    J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2126-2133. PubMed ID: 30067882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive long-term safety of adalimumab from 18 clinical trials in adult patients with moderate-to-severe plaque psoriasis.
    Leonardi C; Papp K; Strober B; Thaçi D; Warren RB; Tyring S; Arikan D; Karunaratne M; Valdecantos WC
    Br J Dermatol; 2019 Jan; 180(1):76-85. PubMed ID: 30169904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial.
    Papp K; Thaçi D; Marcoux D; Weibel L; Philipp S; Ghislain PD; Landells I; Hoeger P; Kotkin C; Unnebrink K; Seyger M; Williams D
    Lancet; 2017 Jul; 390(10089):40-49. PubMed ID: 28478975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn's Disease With up to 6 Years of Follow-Up in the Pyramid Registry.
    DʼHaens G; Reinisch W; Panaccione R; Satsangi J; Petersson J; Bereswill M; Arikan D; Perotti E; Robinson AM; Kalabic J; Alperovich G; Thakkar R; Loftus EV
    Am J Gastroenterol; 2018 Jun; 113(6):872-882. PubMed ID: 29867173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn's Disease: Results of the PYRAMID Registry.
    Loftus EV; Reinisch W; Panaccione R; Berg S; Alperovich G; Bereswill M; Kalabic J; Petersson J; Thakkar R; Robinson AM; D'Haens G
    Inflamm Bowel Dis; 2019 Aug; 25(9):1522-1531. PubMed ID: 30753510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis.
    Burmester GR; Gordon KB; Rosenbaum JT; Arikan D; Lau WL; Li P; Faccin F; Panaccione R
    Adv Ther; 2020 Jan; 37(1):364-380. PubMed ID: 31748904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease.
    Horneff G; Seyger MMB; Arikan D; Kalabic J; Anderson JK; Lazar A; Williams DA; Wang C; Tarzynski-Potempa R; Hyams JS
    J Pediatr; 2018 Oct; 201():166-175.e3. PubMed ID: 30054164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials.
    Leonardi C; Papp K; Strober B; Reich K; Asahina A; Gu Y; Beason J; Rozzo S; Tyring S
    Am J Clin Dermatol; 2011 Oct; 12(5):321-37. PubMed ID: 21834597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
    Kalb RE; Fiorentino DF; Lebwohl MG; Toole J; Poulin Y; Cohen AD; Goyal K; Fakharzadeh S; Calabro S; Chevrier M; Langholff W; You Y; Leonardi CL
    JAMA Dermatol; 2015 Sep; 151(9):961-9. PubMed ID: 25970800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study.
    Cai L; Gu J; Zheng J; Zheng M; Wang G; Xi LY; Hao F; Liu XM; Sun QN; Wang Y; Lai W; Fang H; Tu YT; Sun Q; Chen J; Gao XH; Gu Y; Teixeira HD; Zhang JZ; Okun MM
    J Eur Acad Dermatol Venereol; 2017 Jan; 31(1):89-95. PubMed ID: 27504914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.
    Reich K; Gooderham M; Thaçi D; Crowley JJ; Ryan C; Krueger JG; Tsai TF; Flack M; Gu Y; Williams DA; Thompson EHZ; Paul C
    Lancet; 2019 Aug; 394(10198):576-586. PubMed ID: 31280967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trial.
    Elewski BE; Baker CS; Crowley JJ; Poulin Y; Okun MM; Calimlim B; Geng Z; Reyes Servin O; Rich PA
    J Eur Acad Dermatol Venereol; 2019 Nov; 33(11):2168-2178. PubMed ID: 31304993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial.
    Leonardi C; Langley RG; Papp K; Tyring SK; Wasel N; Vender R; Unnebrink K; Gupta SR; Valdecantos WC; Bagel J
    Arch Dermatol; 2011 Apr; 147(4):429-36. PubMed ID: 21173304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Similar Improvements in Patient-Reported Outcomes Among Rheumatoid Arthritis Patients Treated with Two Different Doses of Methotrexate in Combination with Adalimumab: Results From the MUSICA Trial.
    Kaeley GS; MacCarter DK; Goyal JR; Liu S; Chen K; Griffith J; Kupper H; Garg V; Kalabic J
    Rheumatol Ther; 2018 Jun; 5(1):123-134. PubMed ID: 29574622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies.
    Gottlieb AB; Kalb RE; Langley RG; Krueger GG; de Jong EM; Guenther L; Goyal K; Fakharzadeh S; Chevrier M; Calabro S; Langholff W; Menter A
    J Drugs Dermatol; 2014 Dec; 13(12):1441-8. PubMed ID: 25607786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy.
    Papp K; Crowley J; Ortonne JP; Leu J; Okun M; Gupta SR; Gu Y; Langley RG
    Br J Dermatol; 2011 Feb; 164(2):434-41. PubMed ID: 21083543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.
    Mason KJ; Barker JNWN; Smith CH; Hampton PJ; Lunt M; McElhone K; Warren RB; Yiu ZZN; Griffiths CEM; Burden AD;
    JAMA Dermatol; 2018 May; 154(5):581-588. PubMed ID: 29590279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.